Performance of subgrouped proportional reporting ratios in the US Food and Drug Administration (FDA) adverse event reporting system-Reference-Cited by-同舟云学术

Performance of subgrouped proportional reporting ratios in the US Food and Drug Administration (FDA) adverse event reporting system

Published:2023-03-07 Issue:7 Volume:22 Page:589-597
ISSN:1474-0338
Container-title:Expert Opinion on Drug Safety
language:en
Short-container-title:Expert Opinion on Drug Safety

Author:

Dauner Daniel G.¹^ORCID,Zhang Rui²,Adam Terrence J.³,Leal Eleazar⁴,Heitlage Viviene¹,Farley Joel F.¹^ORCID

Affiliation:

1. Department of Pharmaceutical Care and Health Systems, College of Pharmacy, University of Minnesota, Minneapolis, Minnesota, USA

2. Division of Computational Health Sciences, Department of Surgery, University of Minnesota, Minneapolis, Minnesota, USA

3. Department of Pharmaceutical Care and Health Systems, College of Pharmacy, Institute for Health Informatics, University of Minnesota, Minneapolis, Minnesota, USA

4. Department of Computer Science, Swenson College of Science and Engineering, University of Minnesota, Duluth, Minnesota, USA

Publisher

Informa UK Limited

Subject

Pharmacology (medical),General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/14740338.2023.2182289

Reference34 articles.

1. Impact of Stratification on Adverse Drug Reaction Surveillance

2. Robust discovery of local patterns

3. Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports

4. Good Signal Detection Practices: Evidence from IMI PROTECT

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Safety assessment of Yasmin: Real-world adverse event analysis using the FAERS database;European Journal of Obstetrics & Gynecology and Reproductive Biology;2024-10

2. The evolving role of disproportionality analysis in pharmacovigilance;Expert Opinion on Drug Safety;2024-06-24

3. Evaluation of four machine learning models for signal detection;Therapeutic Advances in Drug Safety;2023-01